ATE69380T1 - Verfahren zur verhuetung der bindung des willebrand-faktors an menschliche blutplaettchen und zur stimulierung der interaktion der plaettchen mit gefaesswaenden. - Google Patents

Verfahren zur verhuetung der bindung des willebrand-faktors an menschliche blutplaettchen und zur stimulierung der interaktion der plaettchen mit gefaesswaenden.

Info

Publication number
ATE69380T1
ATE69380T1 AT85901892T AT85901892T ATE69380T1 AT E69380 T1 ATE69380 T1 AT E69380T1 AT 85901892 T AT85901892 T AT 85901892T AT 85901892 T AT85901892 T AT 85901892T AT E69380 T1 ATE69380 T1 AT E69380T1
Authority
AT
Austria
Prior art keywords
preventing
factor binding
willebrand factor
vessel walls
human platelets
Prior art date
Application number
AT85901892T
Other languages
English (en)
Inventor
Jack J Hawiger
Sheila Timmons
Marek Kloczewiak
Original Assignee
New England Deaconess Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Deaconess Hospital filed Critical New England Deaconess Hospital
Application granted granted Critical
Publication of ATE69380T1 publication Critical patent/ATE69380T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT85901892T 1984-04-10 1985-04-08 Verfahren zur verhuetung der bindung des willebrand-faktors an menschliche blutplaettchen und zur stimulierung der interaktion der plaettchen mit gefaesswaenden. ATE69380T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/598,711 US4666884A (en) 1984-04-10 1984-04-10 Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
PCT/US1985/000590 WO1985004585A1 (en) 1984-04-10 1985-04-08 Method of inhibiting binding of von willebrand factor to human platelets and inducing interaction of platelet with vessel walls
EP85901892A EP0180596B1 (de) 1984-04-10 1985-04-08 Verfahren zur verhütung der bindung des willebrand-faktors an menschliche blutplättchen und zur stimulierung der interaktion der plättchen mit gefässwänden

Publications (1)

Publication Number Publication Date
ATE69380T1 true ATE69380T1 (de) 1991-11-15

Family

ID=24396616

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85901892T ATE69380T1 (de) 1984-04-10 1985-04-08 Verfahren zur verhuetung der bindung des willebrand-faktors an menschliche blutplaettchen und zur stimulierung der interaktion der plaettchen mit gefaesswaenden.

Country Status (6)

Country Link
US (2) US4666884A (de)
EP (1) EP0180596B1 (de)
AT (1) ATE69380T1 (de)
AU (1) AU4159185A (de)
DE (1) DE3584660D1 (de)
WO (1) WO1985004585A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2070116T3 (es) * 1986-05-30 1995-06-01 Scripps Research Inst Peptidos que inhiben la union del factor von willebrand.
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US5340727A (en) * 1987-11-17 1994-08-23 The Scripps Research Institute GPIbα fragments and recombinant DNA expression vectors
AU639409B2 (en) * 1987-12-10 1993-07-29 La Jolla Cancer Research Foundation Conformationally stabilized cell adhesion peptides
US5827821A (en) * 1987-12-10 1998-10-27 The Burnham Institute Conformationally stabilized cell adhesion peptides
AU3149289A (en) * 1988-03-18 1989-09-21 Rockefeller University, The Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor
DE3819079A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Hirudin-derivate mit verzoegerter wirkung
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
AU5939890A (en) * 1989-06-07 1991-01-07 Genentech Inc. Platelet aggregation inhibitors and related molecules
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
US6008193A (en) * 1990-03-02 1999-12-28 Bio-Technology General Corp. Methods of using human von Willebrand factor GPIb binding domain polypeptides
US5612311A (en) 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5298488A (en) * 1990-10-26 1994-03-29 Fuji Photo Film Co., Ltd. CM-chitin derivatives and use thereof
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
US5190873A (en) * 1991-06-21 1993-03-02 California Institute Of Biological Research Hybrid tryptophan aporepressor containing ligand binding sites
AU3071592A (en) * 1991-11-14 1993-06-15 Brigham And Women's Hospital Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality
US6291424B1 (en) 1991-11-14 2001-09-18 Brigham And Women's Hospital Nitrosated and nitrosylated heme proteins
WO1993015760A1 (en) * 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Dual carrier immunogenic construct
US6660267B1 (en) * 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
WO1994014437A1 (en) * 1992-12-21 1994-07-07 Ophidian Pharmaceuticals, Inc. Prevention and treatment of sepsis
US6579696B1 (en) * 1992-12-21 2003-06-17 Promega Corporation Polymyxin B conjugates
US5462752A (en) * 1994-07-28 1995-10-31 Prp, Inc. Inhibition of platelet binding
KR0156678B1 (ko) * 1996-01-11 1998-10-15 이상윤 안지오텐신 전환효소 저해제
WO1998017319A2 (en) * 1996-10-21 1998-04-30 Quadrant Healthcare (Uk) Limited Platelet substitutes and conjugation methods suitable for their preparation
US6184206B1 (en) 1997-09-03 2001-02-06 The Burnham Institute Integrin ligand dissociators
AU7007001A (en) 2000-06-22 2002-01-02 Nitromed Inc Nitrosated and nitrosylated taxanes, compositions and methods of use
US20030003515A1 (en) * 2000-12-05 2003-01-02 Farrell David H. Monocloral antibody-based diagnostic assay for gamma fibrinogen
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP1432447A2 (de) * 2001-09-27 2004-06-30 The Board Of Regents, The University Of Texas System Kombinierte zusammensetzung und methoden zur behandlung der koagulation tumorgefäss
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
CA2578046A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
KR20070101227A (ko) 2004-09-07 2007-10-16 아케믹스 코포레이션 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도
JP4503424B2 (ja) * 2004-11-30 2010-07-14 アルプス電気株式会社 多段スイッチ装置
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
EP2233500A1 (de) 2009-03-20 2010-09-29 LFB Biotechnologies Optimierte Fc Varianten
US20120134984A1 (en) 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
WO2012069433A2 (en) 2010-11-23 2012-05-31 Glaxo Group Limited Antigen binding proteins
JP2014501725A (ja) 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
CN103842380A (zh) 2011-07-27 2014-06-04 葛兰素集团有限公司 融合至Fc结构域的抗VEGF单可变结构域
DK2771022T3 (da) 2011-10-11 2020-09-28 Viela Bio Inc Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
EP2888279A1 (de) 2012-08-22 2015-07-01 Glaxo Group Limited Anti-lrp6-antikörper
HRP20201113T1 (hr) 2013-03-15 2020-10-30 Glaxosmithkline Intellectual Property Development Limited Vežući proteini protiv lag-3
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
HK1231496A1 (zh) 2014-06-20 2017-12-22 豪夫迈．罗氏有限公司 基於chagasin的支架组合物、方法和应用
RU2021133819A (ru) 2015-09-02 2021-12-10 Иммутеп С.A.С. Анти-lag-3 антитела
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2018049275A1 (en) 2016-09-09 2018-03-15 Genentech, Inc. Selective peptide inhibitors of frizzled
NZ784975A (en) 2019-08-06 2025-10-31 Glaxosmithkline Ip Dev Ltd Biopharmacuetical compositions and related methods
JP2024521187A (ja) 2021-05-28 2024-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ガンの治療のための組み合わせ療法
TW202323822A (zh) 2021-08-03 2023-06-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 生藥組合物及穩定同位素標記肽之圖譜定位方法
EP4412713A1 (de) 2021-10-05 2024-08-14 GlaxoSmithKline Intellectual Property Development Ltd Kombinationstherapien zur behandlung von krebs
CN118475353A (zh) 2021-12-17 2024-08-09 Viiv保健公司 用于hiv感染的联合疗法及其用途
JP2025514374A (ja) 2022-04-29 2025-05-02 ２３アンドミー・インコーポレイテッド 抗原結合タンパク質
EP4577569A1 (de) 2022-08-25 2025-07-02 GlaxoSmithKline Intellectual Property Development Ltd Antigenbindende proteine und verwendungen davon
TW202430564A (zh) 2022-10-20 2024-08-01 英商葛蘭素史密斯克藍智慧財產權有限公司 抗原結合蛋白
CR20250219A (es) 2022-11-02 2025-09-18 Viiv Healthcare Uk No 5 Ltd Proteínas de unión a antígeno
AR134489A1 (es) 2023-11-27 2026-01-21 Glaxosmithkline Ip Dev Ltd Proteinas de unión a antígeno
TW202544037A (zh) 2023-12-11 2025-11-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 抗原結合蛋白
WO2025229019A1 (en) 2024-04-30 2025-11-06 VIIV Healthcare UK (No.5) Limited Neutralizing antibody constructs against hiv
WO2025229018A1 (en) 2024-04-30 2025-11-06 VIIV Healthcare UK (No.5) Limited Neutralizing antibody constructs against hiv
WO2025242652A1 (en) 2024-05-23 2025-11-27 Glaxosmithkline Intellectual Property Development Limited Pregnancy associated plasma protein-a (pappa) binding proteins
US20260008843A1 (en) 2024-06-21 2026-01-08 Glaxosmithkline Intellectual Property Development Limited Multispecific antigen binding proteins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384995A (en) * 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
JPS5836308B2 (ja) * 1977-02-10 1983-08-08 大塚製薬株式会社 抗体の製造方法
US4275000A (en) * 1977-08-22 1981-06-23 National Research Development Corporation Peptide macromolecular complexes
US4220722A (en) * 1978-02-10 1980-09-02 Syva Company Method for conjugating to polyamino compounds employing haloacyl groups and compositions prepared thereby
US4303592A (en) * 1980-01-09 1981-12-01 Center For Blood Research, Inc. Amidinophenylmethylsulfonylfluoride
US4423034A (en) * 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
FR2498192A2 (fr) * 1981-01-22 1982-07-23 Pasteur Institut Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications
US4455290A (en) * 1981-04-02 1984-06-19 Research Corporation Inhibition of fibrin polymerization by a peptide isolated from fibrin Fragment D1
US4479898A (en) * 1982-05-18 1984-10-30 Smithkline Beckman Corporation Oligopeptide prodrugs
US4454065A (en) * 1982-05-18 1984-06-12 Smithkline Beckman Corporation Oligopeptide prodrugs
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US4545931A (en) * 1983-01-03 1985-10-08 Scripps Clinic And Research Foundation Synthetic heat-stable enterotoxin polypeptide of Escherichia coli
US4525300A (en) * 1983-01-07 1985-06-25 Japanese Foundation For Cancer Research Human leukemia virus-related peptides, antibodies of the peptides and a process for production of the antibodies

Also Published As

Publication number Publication date
DE3584660D1 (de) 1991-12-19
WO1985004585A1 (en) 1985-10-24
US4703039A (en) 1987-10-27
AU4159185A (en) 1985-11-01
US4666884A (en) 1987-05-19
EP0180596A1 (de) 1986-05-14
EP0180596A4 (de) 1989-05-26
EP0180596B1 (de) 1991-11-13

Similar Documents

Publication Publication Date Title
ATE69380T1 (de) Verfahren zur verhuetung der bindung des willebrand-faktors an menschliche blutplaettchen und zur stimulierung der interaktion der plaettchen mit gefaesswaenden.
DE3586159D1 (de) Zusammensetzung und verfahren zur differenzierung von weissen blutzellen.
ATE253631T1 (de) Eine thrombin-blutfraktion zur verwendung in einem medizinischen verfahren
DE3678489D1 (de) Verfahren zur quantitativen bestimmung von protein c und aktivatorpraeparat zur durchfuehrung des verfahrens.
DE68923981D1 (de) Verfahren zur Bestimmung von Textteilen und Verwendung.
DE3582523D1 (de) Behaelter und verfahren zur aufbewahrung von blut.
FI862756A0 (fi) Fibroektiner.
DE3688980D1 (de) Verfahren zur Multigeschwindigkeitskodierung von Signalen und Einrichtung zur Durchführung dieses Verfahrens.
DE3869490D1 (de) Verfahren zur elektrochemischen behandlung von stoffen.
DE68923419D1 (de) Methode zur Züchtung von Bakterien.
DE3677685D1 (de) Signalkodierungsverfahren und zur ausfuehrung dieses verfahrens.
DE3586006D1 (de) Verfahren und zusammensetzungen zur expression von bti-endo-toxin.
DE3676601D1 (de) Mittel zur injektion von aktiviertem vitamin-d3.
DE3676447D1 (de) Zusammensetzung und verfahren zur bestimmung der peroxidartigen aktivitaet des haemoglobins.
AT389590B (de) Verfahren zur kontinuierlichen, quantitativen bestimmung von schwefeldioxid und anordnung zur durchfuehrung des verfahrens
ATA205288A (de) Verfahren zur gemeinsamen vergasung von fluessigen und festen, staubfoermigen brennstoffen
DE3583875D1 (de) Verfahren zur herstellung von kugelfoermigen vollblut-erythrocyten und fixierung derselben.
DE3867537D1 (de) Mischung von monoklonalen antikoerpern zur bestimmung der creatinkinaseaktivitaet.
ATE116368T1 (de) Vektoren und verbindungen zur expression von zymogen-formen von menschlichem protein c.
DE3884695D1 (de) Träger für gegossene Teile und Methode zur Verwendung des Trägers.
DE3674536D1 (de) Zusammensetzung und verfahren zur herstellung von mineralsalzen.
DE3851304D1 (de) Verfahren und Testzusammensetzung zur Bestimmung von Enzym-Aktivität.
DE3761377D1 (de) Verfahren zur aufarbeitung von 2-merkaptobenzthiazol enthaltenden teeren.
ATA333085A (de) Verfahren zur absicherung von geologischen formationen und bohrungen zur durchfuehrung des verfahrens
AT388748B (de) Vorrichtung zur bestimmung von mikroorganismen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee